DSpace university logo mark
詳細検索
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 学術雑誌論文 >

Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group


ファイル 記述 サイズフォーマット
LeuRes38_76.pdf1.03 MBAdobe PDF本文ファイル

タイトル: Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
著者: Itonaga, Hidehiro / Tsushima, Hideki / Imanishi, Daisuke / Hata, Tomoko / Doi, Yuko / Mori, Sayaka / Sasaki, Daisuke / Hasegawa, Hiroo / Matsuo, Emi / Nakashima, Jun / Kato, Takeharu / Horai, Makiko / Taguchi, Masataka / Matsuo, Masatoshi / Taniguchi, Hiroaki / Makiyama, Junnya / Sato, Shinya / Horio, Kensuke / Ando, Koji / Moriwaki, Yuji / Sawayama, Yasushi / Ogawa, Daisuke / Yamasaki, Reishi / Takasaki, Yumi / Imaizumi, Yoshitaka / Taguchi, Jun / Kawaguchi, Yasuhisa / Yoshida, Shinichiro / Joh, Tatsuro / Moriuchi, Yukiyoshi / Nonaka, Hiroaki / Soda, Hisashi / Fukushima, Takuya / Nagai, Kazuhiro / Kamihira, Shimeru / Tomonaga, Masao / Yanagihara, Katsunori / Miyazaki, Yasushi
発行日: 2014年 1月
出版者: Elsevier Limited
引用: Leukemia Research, 38(1), pp.76-83; 2014
抄録: An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. Factors associated with the loss of sustained MMR were a low daily dose of TKI and the emergence of alternatively spliced BCR-ABL1 mRNA with a 35-nucleotide insertion. Taken together, our results suggest that the search for BCR-ABL1 mutations should be initiated if patients have not achieved MMR following 12 months of TKI treatment.
キーワード: Alternative splicing / BCR-ABL1 / Chronic myelogenous leukemia / Mutation / Resistance
URI: http://hdl.handle.net/10069/34111
ISSN: 01452126
DOI: 10.1016/j.leukres.2013.10.022
権利: © 2013 Elsevier Ltd. / NOTICE: this is the author’s version of a work that was accepted for publication in Leukemia Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Leukemia Research, 38, ISS1, (2014)
資料タイプ: Journal Article
原稿種類: author
出現コレクション:030 学術雑誌論文

引用URI : http://hdl.handle.net/10069/34111

このリポジトリに保管されている文献はすべて著作権により保護されています。
印刷やダウンロード等データの複製は、調査研究・教育または学習を目的とする場合に限定されます。

 

Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace